These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445 [TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Hulot JS; Bura A; Villard E; Azizi M; Remones V; Goyenvalle C; Aiach M; Lechat P; Gaussem P Blood; 2006 Oct; 108(7):2244-7. PubMed ID: 16772608 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of clopidogrel: evidence and perspectives. Yin T; Miyata T Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545 [TBL] [Abstract][Full Text] [Related]
6. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260 [TBL] [Abstract][Full Text] [Related]
7. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Oh IY; Park KW; Kang SH; Park JJ; Na SH; Kang HJ; Koo BK; Jeong YH; Hwang JY; Kwak CH; Park Y; Hwang SJ; Ko YG; Shin DJ; Jang Y; Kim HS Heart; 2012 Jan; 98(2):139-44. PubMed ID: 21700758 [TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Scott SA; Sangkuhl K; Stein CM; Hulot JS; Mega JL; Roden DM; Klein TE; Sabatine MS; Johnson JA; Shuldiner AR; Clin Pharmacol Ther; 2013 Sep; 94(3):317-23. PubMed ID: 23698643 [TBL] [Abstract][Full Text] [Related]
16. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210 [TBL] [Abstract][Full Text] [Related]
17. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055 [TBL] [Abstract][Full Text] [Related]
18. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Price MJ; Tantry US; Gurbel PA Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883 [TBL] [Abstract][Full Text] [Related]